title: Slowing down ALS--is this good or bad?
abstract: The availability of a drug that provides modest relief in ALS without altering its inevitable progression and end, has posed new ethical and economic problems for patients, caregivers and physicians. Early evidence suggests that riluzole does provide a short additional quality of life and economic benefit for patient and society. However, there is a clear need for additional therapies, even if the benefit is minor.
authors.affiliation: Department of Neurology, New England Medical Center, Boston, MA 02111, USA.
authors.forename: T L
authors.initials: TL
authors.lastname: Munsat
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000523:psychology; D003362:Cost-Benefit Analysis; D006801:Humans; D018696:Neuroprotective Agents / Q000191:economics / Q000627:therapeutic use*; D011788:Quality of Life; D019782:Riluzole / Q000191:economics / Q000627:therapeutic use*
chemical_list: D018696:Neuroprotective Agents; D019782:Riluzole